These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34085779)

  • 1. Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy.
    Tortorici MA; Yuraszeck T; Cornblath D; Bril V; Hartung HP; Sobue G; Lewis RA; Merkies ISJ; Lawo JP; Praus M; Durn BL; Mielke O; Ma X; Jauslin P; Pfister M; van Schaik IN;
    CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):839-850. PubMed ID: 34085779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
    Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.
    Mielke O; Bril V; Cornblath DR; Lawo JP; van Geloven N; Hartung HP; Lewis RA; Merkies ISJ; Sobue G; Durn B; Shebl A; van Schaik IN;
    J Peripher Nerv Syst; 2019 Mar; 24(1):72-79. PubMed ID: 30672067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgPro20, the Polyneuropathy and Treatment with Hizentra
    Berger M; Harbo T; Cornblath DR; Mielke O
    Immunotherapy; 2018 Aug; 10(11):919-933. PubMed ID: 29764262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.
    van Schaik IN; Mielke O; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Praus M; Durn BL; Cornblath DR; Merkies ISJ;
    Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):e590. PubMed ID: 31355323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
    Merkies ISJ; van Schaik IN; Léger JM; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Durn BL; Cornblath DR; De Bleecker JL; Sommer C; Robberecht W; Saarela M; Kamienowski J; Stelmasiak Z; Tackenberg B; Mielke O;
    J Peripher Nerv Syst; 2019 Mar; 24(1):48-55. PubMed ID: 30672091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Globulin Subcutaneous (Human) 20% (Hizentra
    Lamb YN; Syed YY; Dhillon S
    CNS Drugs; 2019 Aug; 33(8):831-838. PubMed ID: 31347096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of relapse by inflammatory Rasch-built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy.
    Merkies ISJ; van Schaik IN; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR;
    J Peripher Nerv Syst; 2022 Jun; 27(2):159-165. PubMed ID: 35266243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study.
    Hartung HP; Mallick R; Bril V; Lewis RA; Sobue G; Lawo JP; Mielke O; Durn BL; Cornblath DR; Merkies ISJ; van Schaik IN;
    Eur J Neurol; 2020 Jan; 27(1):196-203. PubMed ID: 31400231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.
    van Schaik IN; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Praus M; Mielke O; Durn BL; Cornblath DR; Merkies ISJ;
    Lancet Neurol; 2018 Jan; 17(1):35-46. PubMed ID: 29122523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic Analysis of Weekly Versus Biweekly IgPro20 Dosing in Patients With Primary Immunodeficiency.
    Rojavin MA; Chapdelaine H; Tortorici MA; Praus M; Baheti G; Zhang Y; Hofmann J; Labrosse R; Dicaire R; Haddad E
    Clin Pharmacol Drug Dev; 2020 Aug; 9(6):664-670. PubMed ID: 31814328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders.
    Broyles R; Rodden L; Riley P; Berger M
    Postgrad Med; 2013 Mar; 125(2):65-72. PubMed ID: 23816772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic analysis of weekly and biweekly IgPro20 (Hizentra®) dosing in patients with primary immunodeficiency.
    Zhang Y; Baheti G; Chapdelaine H; Hofmann J; Rojavin M; Tortorici M; Haddad E
    Int Immunopharmacol; 2020 Apr; 81():106005. PubMed ID: 31806567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseases.
    Li Z; Dumas T; Seth Berry N; McCoy B; Yel L
    Int Immunopharmacol; 2021 Nov; 100():108044. PubMed ID: 34601202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An international multicenter efficacy and safety study of IqYmune in initial and maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: PRISM study.
    Nobile-Orazio E; Pujol S; Kasiborski F; Ouaja R; Corte GD; Bonek R; Cocito D; Schenone A
    J Peripher Nerv Syst; 2020 Dec; 25(4):356-365. PubMed ID: 32808406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy.
    Rajabally YA; Afzal S
    J Neurol; 2019 Feb; 266(2):461-467. PubMed ID: 30556098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manual push technique, an alternative route of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyradiculoneuropathy: A proof-of-concept study.
    Cocito D; Peci E; Rigaldo S; Canavese C; Migliaretti G; Cossa FM
    Clin Neurol Neurosurg; 2020 Nov; 198():106240. PubMed ID: 32971302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrophysiological testing in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin: The Polyneuropathy And Treatment with Hizentra (PATH) study.
    Bril V; Hartung HP; Lawo JP; Durn BL; Mielke O
    Clin Neurophysiol; 2021 Jan; 132(1):226-231. PubMed ID: 33039291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous "bolus" immunoglobulin dose in CIDP: A proof-of concept study.
    Cocito D; Peci E; Romagnolo A; Rigaldo S; Rosso M; Lopiano L; Merola A
    J Neurol Sci; 2017 Sep; 380():54-57. PubMed ID: 28870589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review.
    Lewis RA; Cornblath DR; Hartung HP; Sobue G; Lawo JP; Mielke O; Durn BL; Bril V; Merkies ISJ; Bassett P; Cleasby A; van Schaik IN;
    J Peripher Nerv Syst; 2020 Sep; 25(3):230-237. PubMed ID: 32627277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.